Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | GZMB | P10144 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360127 | 1.00 | CASP3 (0.43) | CASP3GZMBCASP1KDM4EMAPT | |
| SCHEMBL4599097 | 1.00 | CASP3 (0.43) | CASP3GZMBCASP1KDM4EMAPT | |
| SCHEMBL7275397 | 0.85 | CASP1 (0.41) | CASP3GZMBCASP1 | |
| SCHEMBL23288380 | 0.84 | ALDH1A1 (0.39) | CASP3GZMBKDM4EMAPTTHRB | |
| SCHEMBL5454579 | 0.81 | KDM4E (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL11557965 | 0.81 | KDM4E (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL12809931 | 0.81 | CASP3 (0.45) | CASP3GZMBCASP1 | |
| SCHEMBL7275500 | 0.81 | CASP3 (0.45) | CASP3GZMBCASP1 | |
| SCHEMBL200456 | 0.79 | PLA2G2C (0.40) | — | |
| SCHEMBL24809460 | 0.79 | PLA2G2C (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116926141-A | Method for synthesizing acetylated amino acid and oligopeptide by catalyzing food-grade enzyme preparation | 华南理工大学 | 2023-10-24 | — | — | CN | disclosed |
| EP-4006625-A1 | CONTACT LENS AND MOLD FOR MANUFACTURING SAME | Dae Won Pharmaceutical Co., Ltd. (KR) | 2022-06-01 | — | — | EP | disclosed |
| WO-2019190266-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | (주)퓨쳐켐 | 2019-10-03 | — | — | WO | disclosed |
| EP-3034512-B1 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions | TSETI IOULIA (GR) | 2017-12-06 | — | — | EP | disclosed |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. | 2017-07-27 | — | — | US | disclosed |
| EP-3034512-A1 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions | Tseti, Ioulia (GR) | 2016-06-22 | — | — | EP | disclosed |
| US-20160108089-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-04-21 | — | — | US | disclosed |
| CN-104053785-A | Assays For Selecting A Treatment Regimen For A Subject With Depression And Methods For Treatment | GEN HOSPITAL CORP | 2014-09-17 | — | — | CN | disclosed |
| US-20130023646-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-0594760-B1 | POLYACRYLIC ACID BASED OPHTHALMIC COMPOSITIONS | EUROPHTA LAB (MC) | 1998-05-06 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| EP-0594760-A1 | POLYACRYLIC ACID BASED OPHTHALMIC COMPOSITIONS | LABORATOIRE EUROPHTA S.A. (MC) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993000887-A1 | POLYACRYLIC ACID BASED OPHTHALMIC COMPOSITIONS | LABORATOIRE EUROPHTA S.A. (MC) | 1993-01-21 | — | — | WO | disclosed |
| US-5000936-A | Methods for locally-treating allergic disorders with pharmaceutical preparations containing N-acetyl-aspartyl glutamic acid or its salts | THEA (THERAPEUTIQUE ET APPLICATIONS) S.A. (FR) | 1991-03-19 | — | — | US | disclosed |
| US-4593045-A | N-acetyl-L-aspartyl taurine useful as hypertensive agent | Societe a Responsabilite Limite dite: B.F.B. Estudes et Recherches Experimentales (FR) | 1986-06-03 | — | — | US | disclosed |
| EP-0069674-B1 | MEDICINES CONTAINING AN N-ACYL-L-ASPACTYL-TAURINE | SOCIETE BFB (FR) | 1985-04-17 | — | — | EP | disclosed |
| EP-0069674-A1 | Medicines containing an N-acyl-L-aspactyl-taurine | SOCIETE BFB (FR) | 1983-01-12 | — | — | EP | disclosed |
| US-4175084-A | AND AN N-ACYL ASPARTIC ACID CARRIER, FOR PSYCHOLOGICAL DISORDERS, LEARNING ENHANCEMENT AND SLEEP INDUCTION | SENTRALINSTITUTT FOR INDUSTRIELL FORSKNING (NO) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023646-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | CASP3 909/4885GZMB 102/4885CASP1 1259/4885 |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | CASP3 1759/4885GZMB 553/4885CASP1 2538/4885 |
| US-20160108089-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | CASP3 909/4885GZMB 102/4885CASP1 1259/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | CASP3 909/4885GZMB 102/4885CASP1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.